Researchers analyzed data on 7,020 type 2 diabetes patients with cardiovascular disease from the EMPA-REG OUTCOME trial and found that the expected residual years of survival among those who received empagliflozin was 32.1 years at age 45 and 7.7 years at age 80, compared with 27.6 years and 6.7 years among those on placebo, respectively. The findings in the journal Circulation showed that empagliflozin could prolong a patient's life span by an average of 2.5 years, said study lead author Brian Claggett.
Diabetes, CVD patients may improve life expectancy with empagliflozin
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.